TCGA molecular groups of endometrial cancer: Pooled data about prognosis

被引：153

作者：

Raffone, Antonio ^{[1
]}

Travaglino, Antonio ^{[2
]}

Mascolo, Massimo ^{[2
]}

Carbone, Luigi ^{[1
]}

Guida, Maurizio ^{[1
]}

Insabato, Luigi ^{[2
]}

Zullo, Fulvio ^{[1
]}

机构：

[1] Univ Naples Federico II, Sch Med, Gynecol & Obstet Unit, Dept Neurosci Reprod Sci & Dent, Naples, Italy

[2] Univ Naples Federico II, Sch Med, Dept Adv Biomed Sci, Anat Pathol Unit, Via Sergio Pansini 5, I-80131 Naples, Italy

来源：

GYNECOLOGIC ONCOLOGY | 2019年 / 155卷 / 02期

关键词：

Prognosis; Treatment; Endometrium; Risk assessment; PROMISE; CLASSIFICATION; DIAGNOSIS;

D O I：

10.1016/j.ygyno.2019.08.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: After The Cancer Genome Atlas (TCGA) findings, four novel prognostic groups may direct the management of endometrial cancer (EC): POLE-mutated/ultramutated (POLEmt), microsatellite-instable/hypermutated (MSI), copy-number-low/p53-wild-type (p53wt), and copy-number-high/p53-mutated (p53mt). However, data about prognosis in each group are different across the studies, and definitive pooled estimates are lacking after validation series. Such data may be crucial in directing clinical study design and establishing the optimal tailored management of patients. Aim: To provide pooled estimates of hazard ratio (HR) for overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS) in each prognostic group. Materials and methods: A systematic review and meta-analysis was performed by searching 7 electronic databases, from their inception to April 2019, for studies assessing prognosis in each TCGA EC group. Both univariable and multivariable HR analysis was performed for OS, DSS and PFS in each group, using p53wt as reference group. Results: Six studies with 2818 patients were included. Regarding OS, pooled HRs were 3.179 and 1.986 for p53mt group, 1.522 and 1.192 for MSI group, and 0.589 and 0.795 for POLEmt group at univariable and multivariable analyses, respectively. Regarding DSS, pooled HR were 5.052 and 2.133 for p53mt group, 1.965 and 1.068 for MSI group, and 0.552 and 0.325 for POLEmt group at univariable and multivariable analyses, respectively. Regarding PFS, pooled HR were 3.512 and 1.833 for p53mt group, 1.354 and 0.817 for MSI group, and 0.287 and 0.217 for POLEmt group at univariable and multivariable analyses, respectively. Conclusions: Prognosis of p53mt group is consistently the worst one and is further worsened by unfavorable clinicopathological factors. Prognosis of MSI group overlaps with p53wt group but is worsened by unfavorable clinicopathological factors. Prognosis of POLEmt group is the best one and does not seem to be significantly affected by clinicopathological factors. (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：374 / 383

页数：10

共 40 条

[1]

Abu-Rustum NR, 2019, NCCN CLIN PRACTICE G

[2]

[Anonymous], 2010, INT J SURG, DOI [DOI 10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097, DOI 10.1371/JOURNAL.PMED.1000097]

[3] Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative [J].

Auguste, Aurelie ;

Genestie, Catherine ;

De Bruyn, Marco ;

Adam, Julien ;

Le Formal, Audrey ;

Drusch, Francoise ;

Pautier, Patricia ;

Crosbie, Emma J. ;

MacKay, Helen ;

Kitchener, Henry C. ;

Powell, Melanie ;

Pollock, Pamela M. ;

Mileshkin, Linda ;

Edmondson, Richard J. ;

Nout, Remi ;

Nijman, Hans W. ;

Creutzberg, Carien L. ;

Bosse, Tjalling ;

Leary, Alexandra .

MODERN PATHOLOGY, 2018, 31 (12) :1851-1861

[4] Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups [J].

Bosse, Tjalling ;

Nout, Remi A. ;

McAlpine, Jessica N. ;

McConechy, Melissa K. ;

Britton, Heidi ;

Hussein, Yaser R. ;

Gonzalez, Carlene ;

Ganesan, Raji ;

Steele, Jane C. ;

Harrison, Beth T. ;

Oliva, Esther ;

Vidal, August ;

Matias-Guiu, Xavier ;

Abu-Rustum, Nadeem R. ;

Levine, Douglas A. ;

Gilks, C. Blake ;

Soslow, Robert A. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (05) :561-568

[5] ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up [J].

Colombo, N. ;

Creutzberg, C. ;

Amant, F. ;

Bosse, T. ;

Gonzalez-Martin, A. ;

Ledermann, J. ;

Marth, C. ;

Nout, R. ;

Querleu, D. ;

Mirza, M. R. ;

Sessa, C. .

ANNALS OF ONCOLOGY, 2016, 27 (01) :16-41

[6] Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Colombo, N. ;

Preti, E. ;

Landoni, F. ;

Carinelli, S. ;

Colombo, A. ;

Marini, C. ;

Sessa, C. .

ANNALS OF ONCOLOGY, 2013, 24 :33-38

[7] An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer [J].

Cosgrove, Casey M. ;

Tritchler, David L. ;

Cohn, David E. ;

Mutch, David G. ;

Rush, Craig M. ;

Lankes, Heather A. ;

Creasman, William T. ;

Miller, David S. ;

Ramirez, Nilsa C. ;

Geller, Melissa A. ;

Powell, Matthew A. ;

Backes, Floor J. ;

Landrum, Lisa M. ;

Timmers, Cynthia ;

Suarez, Adrian A. ;

Zaino, Richard J. ;

Pearl, Michael L. ;

DiSilvestro, Paul A. ;

Lele, Shashikant B. ;

Goodfellow, Paul J. .

GYNECOLOGIC ONCOLOGY, 2018, 148 (01) :174-180

[8] Prognostic factors and patterns of recurrence in lymphovascular space invasion positive women with stage IIIC endometriod endometrial cancer [J].

Cuylan, Zeliha F. ;

Oz, Murat ;

Ozkan, Nazli T. ;

Comert, Gunsu K. ;

Sahin, Hanifi ;

Turan, Taner ;

Akbayir, Ozgur ;

Kuscu, Esra ;

Celik, Husnu ;

Dede, Murat ;

Gungor, Tayfun ;

Meydanli, Mehmet M. ;

Ayhan, Ali .

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (06) :1140-1149

[9] Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial [J].

de Boer, Stephanie M. ;

Powell, Melanie E. ;

Mileshkin, Linda ;

Katsaros, Dionyssios ;

Bessette, Paul ;

Haie-Meder, Christine ;

Ottevanger, Petronella B. ;

Ledermann, Jonathan A. ;

Khaw, Pearly ;

D'Amico, Romerai ;

Fyles, Anthony ;

Baron, Marie-Helene ;

Jurgenliemk-Schulz, Ina M. ;

Kitchener, Henry C. ;

Nijman, Hans W. ;

Wilson, Godfrey ;

Brooks, Susan ;

Gribaudo, Sergio ;

Provencher, Diane ;

Hanzen, Chantal ;

Kruitwagen, Roy F. ;

Smit, Vincent T. H. B. M. ;

Singh, Naveena ;

Do, Viet ;

Lissoni, Andrea ;

Nout, Remi A. ;

Feeney, Amanda ;

Verhoeven-Adema, Karen W. ;

Putter, Hein ;

Creutzberg, Carien L. .

LANCET ONCOLOGY, 2019, 20 (09) :1273-1285

[10] Integrated genomic characterization of endometrial carcinoma [J].

Getz, Gad ;

Gabriel, Stacey B. ;

Cibulskis, Kristian ;

Lander, Eric ;

Sivachenko, Andrey ;

Sougnez, Carrie ;

Lawrence, Mike ;

Kandoth, Cyriac ;

Dooling, David ;

Fulton, Robert ;

Fulton, Lucinda ;

Kalicki-Veizer, Joelle ;

McLellan, Michael D. ;

O'Laughlin, Michelle ;

Schmidt, Heather ;

Wilson, Richard K. ;

Ye, Kai ;

Ding, Li ;

Mardis, Elaine R. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Lee, Darlene ;

Li, Haiyan I. ;

Marra, Marco A. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Plettner, Patrick ;

Schein, Jacqueline E. ;

Sipahimalani, Payal ;

Tam, Angela ;

Varhol, Richard J. ;

Robertson, A. Gordon ;

Pashtan, Itai ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Schumacher, Steven E. ;

Tabak, Barbara .

NATURE, 2013, 497 (7447) :67-73

← 1 2 3 4 →